{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:13:20Z","timestamp":1792872800874,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jbo.2024.100656","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:11:15Z","timestamp":1734336675000},"page":"100656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS"],"prefix":"10.1016","volume":"50","author":[{"given":"Francesco","family":"Bertoldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Eller-Vainicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Mauceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2024.100656_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment","author":"Menges","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0010","unstructured":"WHO, Breast cancer, 2021 (n.d.). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer (accessed June 28, 2022)."},{"key":"10.1016\/j.jbo.2024.100656_b0015","unstructured":"World Cancer Research Fund International, Breast cancer statistics, World Cancer Research Fund International (n.d.). https:\/\/www.wcrf.org\/cancer-trends\/breast-cancer-statistics\/ (accessed August 31, 2022)."},{"key":"10.1016\/j.jbo.2024.100656_b0020","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0030","unstructured":"S.W., S.-S.T.L., S.H. and S.L.E. Leslie, Prostate Cancer. StatPearls, (2023). https:\/\/www.scirp.org\/reference\/referencespapers?referenceid=3666607 (accessed December 9, 2024)."},{"key":"10.1016\/j.jbo.2024.100656_b0035","unstructured":"AIOM-AIRTUM, AIOM-AIRTUM: I numeri del cancro in Italia 2022, (2022) 1\u2013268."},{"key":"10.1016\/j.jbo.2024.100656_b0040","unstructured":"World Health Organization, Global Cancer Observatory \u2013 GLOBOCAN 2020, (n.d.). https:\/\/gco.iarc.fr\/databases.php (accessed September 2, 2021)."},{"key":"10.1016\/j.jbo.2024.100656_b0045","unstructured":"AIOM - Metastasi Ossee e Salute dell\u2019Osso 2021, Linee guida Metastasi Ossee e Salute dell\u2019Osso AIOM 2021, (n.d.). https:\/\/www.aiom.it\/linee-guida-aiom-2021-metastasi-ossee-e-salute-dellosso\/ (accessed October 24, 2023)."},{"key":"10.1016\/j.jbo.2024.100656_b0050","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0055","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jbo.2024.100656_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-021-00835-2","article-title":"Cancer treatment\u2013induced bone loss (CTIBL): state of the art and proper management in breast cancer patients on endocrine therapy","volume":"22","author":"Diana","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0065","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0070","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw \u2013 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12903-023-02732-6","article-title":"MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series","volume":"23","author":"Mauceri","year":"2023","journal-title":"BMC Oral Health"},{"key":"10.1016\/j.jbo.2024.100656_b0080","article-title":"Joint report SIPMO-SIOMMMS sulla MRONJ in pazienti in cura con antiriassorbitivi per prevenire la CTIBL","author":"Campisi","year":"2024","journal-title":"Dent. Cadmos"},{"key":"10.1016\/j.jbo.2024.100656_b0085","doi-asserted-by":"crossref","unstructured":"V. Fusco, R. Mauceri, G. Campisi, A. Bedogni, RE: American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws\u20142022 Update: Quantitative Risk Assessment and Controversial Issues, 80 (2022) 1871\u20131873.","DOI":"10.1016\/j.joms.2022.07.143"},{"key":"10.1016\/j.jbo.2024.100656_b0090","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s00520-020-05882-3","article-title":"Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis","volume":"29","author":"Srivastava","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0095","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years","volume":"104","author":"Watts","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jbo.2024.100656_b0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2017.01.028","article-title":"Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?","volume":"76","author":"Palmerini","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2024.100656_b0110","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00784-013-1012-5","article-title":"Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer","volume":"18","author":"Rugani","year":"2014","journal-title":"Clin. Oral Invest."},{"key":"10.1016\/j.jbo.2024.100656_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2024.100656_b0135","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","article-title":"Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01\/04)","volume":"31","author":"Rathbone","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbo.2024.100656_b0150","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00520-020-05748-8","article-title":"Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)","volume":"29","author":"Kizub","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0155","article-title":"Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer (BOOG 2006-04): randomized phase III TEAM-IIB trial","volume":"68","author":"Vliek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0160","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/S1470-2045(20)30066-8","article-title":"Adjuvant denosumab in early breast-cancer","volume":"21","author":"Fusco","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0165","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1080\/14656566.2021.1948012","article-title":"Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer","volume":"22","author":"Moussa","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jbo.2024.100656_b0170","first-page":"11","article-title":"Androgen deprivation therapy: indications, methods of utilization, side effects and their management","volume":"27","author":"Magee","year":"2020","journal-title":"Can. J. Urol."},{"key":"10.1016\/j.jbo.2024.100656_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104534","article-title":"Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: a narrative review on behalf of the meet-URO Group","volume":"204","author":"Giunta","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jbo.2024.100656_b0180","doi-asserted-by":"crossref","DOI":"10.1210\/er.2014-1024","article-title":"Sex steroid actions in male bone","author":"Vanderschueren","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jbo.2024.100656_b0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00198-015-3246-3","article-title":"Elevated incidence of fractures in women with invasive breast cancer","volume":"27","author":"Edwards","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2024.100656_b0190","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jbo.2024.100656_b0195","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","article-title":"Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications","volume":"111","author":"Shao","year":"2013","journal-title":"BJU Int."},{"key":"10.1016\/j.jbo.2024.100656_b0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pds.2258","article-title":"Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States","volume":"21","author":"Beebe-Dimmer","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jbo.2024.100656_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","article-title":"Guidelines for the diagnosis, prevention and management of osteoporosis","volume":"68","author":"Rossini","year":"2016","journal-title":"Reumatismo"},{"key":"10.1016\/j.jbo.2024.100656_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0215","doi-asserted-by":"crossref","first-page":"75646","DOI":"10.18632\/oncotarget.17980","article-title":"The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation","volume":"8","author":"Cianferotti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbo.2024.100656_b0220","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0225","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2024.100656_b0230","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2024.100656_b0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"ATAC Trialists\u2019 Group","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0240","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14737140.2016.1192466","article-title":"Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis","volume":"16","author":"Abdel-Rahman","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.jbo.2024.100656_b0245","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0250","doi-asserted-by":"crossref","unstructured":"AIFA, Nota 79 (2015) 4\u201312.","DOI":"10.1177\/1741134315618535"},{"key":"10.1016\/j.jbo.2024.100656_b0255","first-page":"163","article-title":"Cancer treatment-induced bone loss: role of denosumab in non-metastatic breast cancer","volume":"14","author":"Dhabhar","year":"2022","journal-title":"Breast Cancer (dove Med. Press)"},{"key":"10.1016\/j.jbo.2024.100656_b0260","article-title":"Efficacy of antiresorptive drugs on bone mineral density in post-menopausal women with early breast cancer receiving adjuvant aromatase inhibitors: a systematic review of randomized controlled","author":"de Sire","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.jbo.2024.100656_b0265","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1556331621995846","article-title":"Vertebral fractures after denosumab discontinuation in breast cancer survivors: a single institution experience","volume":"17","author":"Yeung","year":"2021","journal-title":"HSS J."},{"key":"10.1016\/j.jbo.2024.100656_b0275","doi-asserted-by":"crossref","unstructured":"E. Tsourdi, M.C. Zillikens, C. Meier, J.J. Body, E. Gonzalez Rodriguez, A.D. Anastasilakis, B. Abrahamsen, E. Mccloskey, L.C. Hofbauer, N. Gua\u00f1abens, B. Obermayer-Pietsch, S.H. Ralston, R. Eastell, J. Pepe, A. Palermo, B. Langdahl, Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS, 106 (n.d.) 264\u2013281. https:\/\/pubmed.ncbi.nlm.nih.gov\/33103722\/ (accessed November 23, 2022).","DOI":"10.1210\/clinem\/dgaa756"},{"key":"10.1016\/j.jbo.2024.100656_b0280","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11739-018-1874-2","article-title":"Guidelines for the management of osteoporosis and fragility fractures","volume":"14","author":"Nuti","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.jbo.2024.100656_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115501","article-title":"On the pharmacological evaluation of bisphosphonates in humans","volume":"139","author":"Cremers","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2024.100656_b0290","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12355","article-title":"The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review","volume":"78","author":"Sohn","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jbo.2024.100656_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100470","article-title":"Management of bone metastasis with zoledronic acid: a systematic review and Bayesian network meta-analysis","volume":"39","author":"Lorange","year":"2023","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0300","doi-asserted-by":"crossref","DOI":"10.1111\/odi.14887","article-title":"Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)","author":"Bedogni","year":"2024","journal-title":"Oral Dis."},{"key":"10.1016\/j.jbo.2024.100656_b0305","series-title":"Raccomandazioni clinico-terapeutiche sull\u2019osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione","author":"Campisi","year":"2020"},{"key":"10.1016\/j.jbo.2024.100656_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106689","article-title":"Challenges in the diagnosis of oral squamous cell carcinoma mimicking medication-related osteonecrosis of the jaws: a multi-hospital-based case series","volume":"151","author":"Mauceri","year":"2024","journal-title":"Oral Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0315","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0320","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10266-018-0362-5","article-title":"Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis","volume":"106","author":"Voss","year":"2018","journal-title":"Odontology"},{"key":"10.1016\/j.jbo.2024.100656_b0325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.oooo.2019.03.002","article-title":"Comparison of findings of radiographic and fractal dimension analyses on panoramic radiographs of patients with early-stage and advanced-stage medication-related osteonecrosis of the jaw","volume":"128","author":"\u015eahin","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.jbo.2024.100656_b0330","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/odi.13160","article-title":"Workshop of European task force on medication-related osteonecrosis of the jaw\u2014current challenges","volume":"25","author":"Schiodt","year":"2019","journal-title":"Oral Dis."},{"key":"10.1016\/j.jbo.2024.100656_b0335","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"2020","key":"10.1016\/j.jbo.2024.100656_b0340","first-page":"1","article-title":"Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update","volume":"17","author":"Campisi","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.jbo.2024.100656_b0345","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5624\/isd.20200230","article-title":"CBCT imaging and histopathological characteristics of osteoradionecrosis and medication-related osteonecrosis of the jaw","volume":"51","author":"Ogura","year":"2021","journal-title":"Imaging Sci. Dent"},{"key":"10.1016\/j.jbo.2024.100656_b0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15254-y","article-title":"Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction","volume":"12","author":"Moreno-Rabi\u00e9","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbo.2024.100656_b0355","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5624\/isd.20220202","article-title":"Texture analysis in cone-beam computed tomographic images of medication-related osteonecrosis of the jaw","volume":"53","author":"Queiroz","year":"2023","journal-title":"Imaging Sci. Dent."},{"key":"10.1016\/j.jbo.2024.100656_b0360","doi-asserted-by":"crossref","DOI":"10.1259\/dmfr.20200417","article-title":"Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review","volume":"50","author":"Wongratwanich","year":"2021","journal-title":"Dentomaxillofac. Radiol."},{"key":"10.1016\/j.jbo.2024.100656_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.110916","article-title":"Radiologic findings of osteonecrosis, osteoradionecrosis, osteomyelitis and jaw metastatic disease with cone beam CT","volume":"165","author":"Yfanti","year":"2023","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.jbo.2024.100656_b0370","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0375","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","article-title":"Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention","volume":"125","author":"Owosho","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.jbo.2024.100656_b0380","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-022-06940-8","article-title":"The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists","author":"Mauceri","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0385","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.joms.2009.10.026","article-title":"Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction","volume":"68","author":"Saia","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0390","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0395","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/odi.13294","article-title":"Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents","volume":"26","author":"Nicolatou-Galitis","year":"2020","journal-title":"Oral Dis."},{"key":"10.1016\/j.jbo.2024.100656_b0400","article-title":"Histological findings of osteonecrosis spotted prior to tooth extractions. Should we consider tooth extraction still the main trigger event?","author":"Mauceri","year":"2021","journal-title":"Qeios"},{"key":"10.1016\/j.jbo.2024.100656_b0405","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/j.oooo.2012.08.442","article-title":"Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw","volume":"117","author":"Heufelder","year":"2014","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.jbo.2024.100656_b0410","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/odi.13556","article-title":"Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake \u2013 a randomized pilot trial","volume":"27","author":"Ristow","year":"2021","journal-title":"Oral Dis."},{"key":"10.1016\/j.jbo.2024.100656_b0415","doi-asserted-by":"crossref","DOI":"10.1111\/odi.15006","article-title":"Reduction of MRONJ risk after exodontia by virtue of ozone infiltration: a randomized clinical trial","author":"Di Fede","year":"2024","journal-title":"Oral Dis."},{"key":"10.1016\/j.jbo.2024.100656_b0420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2334\/josnusd.21-0016","article-title":"Lack of evidence in reducing risk of mronj after teeth extractions with systemic antibiotics","volume":"63","author":"Cabras","year":"2021","journal-title":"J. Oral Sci."},{"key":"10.1016\/j.jbo.2024.100656_b0425","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/SCS.0000000000002564","article-title":"Medication-related osteonecrosis of the jaw around dental implants: Implant surgery-triggered or implant presence-triggered osteonecrosis?","volume":"27","author":"Giovannacci","year":"2016","journal-title":"J. Craniofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0430","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jormas.2019.04.012","article-title":"Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis: case series and literature review","volume":"121","author":"Escobedo","year":"2020","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0435","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/clr.12088","article-title":"Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment","volume":"25","author":"Kwon","year":"2014","journal-title":"Clin. Oral Implant Res."},{"key":"10.1016\/j.jbo.2024.100656_b0440","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","article-title":"Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study","volume":"47","author":"Vescovi","year":"2011","journal-title":"Oral Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0445","doi-asserted-by":"crossref","DOI":"10.1186\/s13005-021-00280-4","article-title":"A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis","volume":"17","author":"Campisi","year":"2021","journal-title":"Head Face Med."},{"key":"10.1016\/j.jbo.2024.100656_b0450","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajoms.2020.09.002","article-title":"Adverse events caused by the discontinuation of anti-resorptive agents during treatment for anti-resorptive agent-related osteonecrosis of the jaw: a single-center cohort study","volume":"33","author":"Yoshida","year":"2021","journal-title":"J. Oral Maxillofac. Surg. Med. Pathol."},{"key":"10.1016\/j.jbo.2024.100656_b0455","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","article-title":"A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2024.100656_b0460","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jbo.2024.100656_b0465","doi-asserted-by":"crossref","DOI":"10.3803\/EnM.2024.2047","article-title":"Association of delayed denosumab dosing with increased risk of fractures: a population-based retrospective study","author":"Kim","year":"2024","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.jbo.2024.100656_b0470","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00520-016-3492-8","article-title":"Response to letter to the Editors\u2014safety of long-term denosumab therapy","volume":"25","author":"Stopeck","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2024.100656_b0475","article-title":"Curative rates of medication-related osteonecrosis of the jaw following application of the SICMF-SIPMO surgical treatment algorithm","author":"Bettini","year":"2021","journal-title":"Qeios"},{"key":"10.1016\/j.jbo.2024.100656_b0480","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.joms.2015.09.024","article-title":"Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw","volume":"73","author":"Ruggiero","year":"2015","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0485","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.joms.2013.12.007","article-title":"Management of antiresorptive osteonecrosis of the jaws with primary surgical resection","volume":"72","author":"Carlson","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0490","doi-asserted-by":"crossref","first-page":"8432","DOI":"10.3390\/ijerph18168432","article-title":"The treatment of medication-related osteonecrosis of the jaw (Mronj): a systematic review with a pooled analysis of only surgery versus combined protocols","volume":"18","author":"Di Fede","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.jbo.2024.100656_b0495","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0500","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.joms.2016.12.014","article-title":"Extensive surgical procedures result in better treatment outcomes for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis","volume":"75","author":"Kim","year":"2017","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0505","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11185307","article-title":"Ozone infiltration for osteonecrosis of the jaw therapy: a case series","volume":"11","author":"Di Fede","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jbo.2024.100656_b0510","first-page":"1","article-title":"Oral-health-related quality of life after surgical treatment of osteonecrosis of the jaws","volume":"00","author":"Oteri","year":"2017","journal-title":"J. Craniofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0515","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.oraloncology.2011.02.024","article-title":"Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis","volume":"47","author":"Bedogni","year":"2011","journal-title":"Oral Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0520","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/jbmr.3191","article-title":"Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis","volume":"32","author":"Hayashida","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2024.100656_b0525","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jbo.2024.100656_b0530","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jcms.2017.07.014","article-title":"Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws \u2013 a retrospective cohort study","volume":"45","author":"Martins","year":"2017","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2024.100656_b0535","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the american society for bone and mineral research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2024.100656_b0540","doi-asserted-by":"crossref","first-page":"279","DOI":"10.11005\/jbm.2021.28.4.279","article-title":"Medication related osteonecrosis of the jaw: 2021 position statement of the korean society for bone and mineral research and the korean association of oral and maxillofacial surgeons","volume":"28","author":"Kim","year":"2021","journal-title":"J. Bone Metab."},{"key":"10.1016\/j.jbo.2024.100656_b0545","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Japanese Allied Committee On Osteonecrosis Of The Jaw","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jbo.2024.100656_b0550","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-014-2622-8","article-title":"Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw","volume":"25","author":"Kim","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jbo.2024.100656_b0555","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecl.2024.08.003","article-title":"Latest on anabolic agents for osteoporosis treatment","volume":"53","author":"di Filippo","year":"2024","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.jbo.2024.100656_b0565","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.20.01633","article-title":"Are we ready to use teriparatide to treat medication-related osteonecrosis of the jaw in clinical practice?","volume":"38","author":"Ripamonti","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2024.100656_b0570","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J. Clin. Densitometry"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424001362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424001362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:35:15Z","timestamp":1737333315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137424001362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":114,"alternative-id":["S2212137424001362"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100656","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100656"}}